Table 3 Preoperative Ejection Fraction and Postoperative Causes of Death in the 2 Groups
First Author | Preoperative EF (MIL Group) | Preoperative EF (Ctrl Group) | No. of Death (Death/Total, MIL Group) | No. of Death (Death/Total, Ctrl Group) | Cause of Death (MIL Group) | Cause of Death (Ctrl Group) | Adverse Effects (MIL Group) | Adverse Effects (Ctrl Group) | ||
|---|---|---|---|---|---|---|---|---|---|---|
Arbeus [38] | 59 ± 12 | 63 ± 9 | 1 | 22 | 0 | 22 | Not specified | No death | No adverse events or side effects | |
Couture [39] | 51 ± 15 | 50 ± 13 | 2 | 25 | 0 | 25 | Multiple organ failure (2) | No death | Acute renal failure (2) | Acute renal failure (1) |
Doolan [40] | Not specified | Not specified | 0 | 15 | 0 | 15 | No death | No death | No adverse events or side effects | |
Guo [9] | 35 ± 4 | 35 ± 5 | 1 | 31 | 1 | 31 | Not specified | Not specified | Not specified | |
Hadadzadeh [41] | 29 ± 5.5 | 28.6 ± 5.6 | 1 | 40 | 1 | 40 | Cardiac shock | Cardiac shock | CVA, Renal failure (1) | CVA, Renal failure (3) |
Hamada [42] | Not specified | Not specified | 0 | 20 | 0 | 10 | No death | No death | No adverse events or side effects | |
Hayashida [43] | Not specified | Not specified | 0 | 12 | 0 | 12 | No death | No death | No serious adverse effects | Low output syndrome (1) |
Jebeli [44] | 31.8 ± 3.2 | 34.5 ± 1.4 | 0 | 35 | 2 | 35 | No death | Cardiogenic shock (2) | No adverse events or side effects | |
Jo [45] | 45 ± 14 | 51 ± 13 | 0 | 20 | 0 | 20 | No death | No death | Renal failure (1) | Renal failure (2) |
Kwak [46] | Not specified | Not specified | 0 | 29 | 0 | 33 | No death | No death | No adverse events or side effects | |
Lee [32] | 50 ± 17 | 57 ± 8 | 0 | 24 | 0 | 26 | No death | No death | No adverse events or side effects | |
Möllhoff [47] | Not specified | Not specified | 0 | 11 | 0 | 11 | No death | No death | No adverse events or side effects | |
Shi [53] | Not specified | Not specified | 1 | 25 | 1 | 24 | Not specified | Not specified | Not specified | |
Song [54] | 55.3 ± 15.3 | 51.5 ± 16.7 | 1 | 31 | 1 | 31 | Not specified | Not specified | Not specified | |
Yamaguchi [55] | 64.1 ± 8 | 65.2 ± 8.5 | 0 | 14 | 0 | 14 | No death | No death | Not specified | |
Yamaura [56] | Not specified | Not specified | 0 | 10 | 0 | 10 | No death | No death | No adverse events or side effects | |